SCAN-MP (Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations) COVID-19 Suppplement

项目摘要 COVID-19是一种全球性大流行病，对患有心脏病的少数老年人造成不成比例的影响， 多种慢性疾病人口稠密的城市中心，社会经济 包括纽约市和波士顿在内的弱势群体受COVID-19影响最大。扫描- MP（在少数人群中使用核成像筛查心脏淀粉样变性，R 01 HL 139671）是一种 NHLBI资助的前瞻性队列研究，招募了目标800名黑人或加勒比海西班牙裔中的123名 在强制性招募暂停之前患有心力衰竭的60岁以上受试者 流行病SCAN-MP参与者的资料与已知的COVID风险最高的人相匹配- 19.在这个应用程序中，我们建议利用成功的招聘和保留技术的 SCAN-MP基础设施，以促进我们对SARS CoV-2感染流行的理解， 解开已知与感染相关的人口、社会和环境因素。而 缓解是应对COVID-19传播的主要公共卫生战略，可能特别是 对于那些资源有限的人或那些与他人居住在物理上接近的人来说，遵守这些规定具有挑战性 CDC的建议，也许解释了观察到的感染率增加。成功 从大流行中的出现将取决于人群中先前SARS CoV-2感染的证据。 鉴于无症状感染很常见，血清学检测可能在下一阶段发挥关键作用 恢复的机会血清学检测已在哥伦比亚大学得到验证，具有高度敏感性和特异性， 定量ELISA为基础的测定，以检测抗体的SARS-CoV-2，我们建议利用这一点， study.我们的目标是（1）确定有既往COVID证据的SCAN-MP参与者的比例- 通过抗体检测19感染，（2）确定SCAN-MP参与者遵守CDC的能力 缓解建议。然后，我们将探讨感染率和缓解依从性如何与 收入和生活条件等社会经济因素，以及卫生知识普及措施， 对卫生系统的信任/参与，以及感知到的歧视。我们将探讨是否存在 和/或SARS CoV-2病毒特异性抗体的滴度将与未来的COVID-19感染相关， 以及一年时间内的不良结果（住院和死亡）。我们是唯一 考虑到我们招募城市少数族裔心脏病患者的能力， 具有COVID-19发病率/死亡率高风险的疾病， SARS CoV-2的抗体，并在社区参与研究方面建立了专业知识。成功 这些目标的完成有可能为高风险地区缓解战略的实施提供信息， 为解决2019冠状病毒病大流行提供有用的重要数据。

Project Summary COVID-19 is a global pandemic that disproportionately affects minority older adults with cardiac disease and multiple chronic conditions. Densely populated urban centers with a high proportion of socioeconomically disadvantaged persons, including New York City (NYC) and Boston, are most impacted by COVID-19. SCAN- MP (Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations, R01HL139671) is a NHLBI funded, prospective cohort study that enrolled 123 of a target 800 Black or Caribbean Hispanic participants over the age of 60 years with heart failure prior to the mandatory recruitment pause for the pandemic. The profile of the SCAN-MP participant matches those known to be at highest risk from COVID- 19. In this application, we propose to leverage the successful recruitment and retention techniques of the SCAN-MP infrastructure to advance our understanding of the prevalence of SARS CoV-2 infection and disentangle the demographic, social, and environmental factors known to be associated with infection. While mitigation is the primary public health strategy to address the spread of COVID-19, it may be particularly challenging for those with resource limitations or those who live in close physical proximity to others to comply with CDC recommendations, perhaps accounting for the observed increase in infection rates. Successful emergence from the pandemic will depend upon evidence of prior SARS CoV-2 infection in the population. Given that asymptomatic infection is common, serologic testing will likely play a critical role in the next phase of recovery. Serologic testing has been validated at Columbia University with a highly sensitive and specific, quantitative ELISA-based assay to detect antibodies to SARS-CoV-2 that we propose to leverage in this study. Our objectives are to (1) define the proportion of SCAN-MP participants with evidence of prior COVID- 19 infection by antibody testing, (2) determine the capacity of SCAN-MP participants to comply with CDC mitigation recommendations. We will then explore how infection rate and mitigation compliance interact with socio-economic factors such as income and living conditions, as well as measures of health literacy, trust/engagement in the health system, and perceived discrimination. We will explore whether the presence and/or titer of antibodies specific for SARS CoV-2 virus will be associated with future COVID-19 infection as well as adverse outcomes (hospitalizations and mortality) over a one-year time period. We are uniquely positioned to perform these studies quickly given our ability to recruit an urban, minority cohort with cardiac disease at high risk for COVID-19 morbidity/mortality, expertise in the performance of serologic testing for antibodies to SARS CoV-2, and established expertise in community engaged research. Successful completion of these Aims has the potential to inform implementation of mitigation strategies in high-risk populations and contribute important data useful for the resolution of the COVID-19 pandemic.